Encapsulation of exenatide in poly-(d,l-lactide- co -glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes
Common eligibility criteria may include: BMI of 30 or higher BMI of 27 or higher with at least one weight-related health condition History of failed diet attempts or weight regain Appetite, cravings, or portion control challenges Metabolic risk factors such as insulin resistance, elevated glucose, high cholesterol, or hypertension Need for physician-supervised weight loss due to medical complexity Eligibility must be determined through a medical consultation
Conclusion: Use of GLP-1RAs was associated with higher 18-month risk for ION than use of SGLT2is and DPP4is, although absolute risk remained very low
You might have explored hormonal therapies or lifestyle changes, only to find your desire remains low
Ideal application areas include the inside of arms, thighs, torso, and tops of feet